RxDoctor Payments Data

Margaret Dodson

Women's Health · Longview, TXNPI 1780987289

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 48.5% of the total. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,839in general payments, 2019–2025

Across 242 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$2K
  • Merck$445
  • Teva Pharmaceuticals USA, Inc.$215
  • GSK$120
  • Johnson & Johnson$116
  • plus $406 from 10 others

What the payments were for

  • Food & beverage$5,73998%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,839 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.

See all women's health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala53$220,481
GenvoyaElviteg/Cob/Emtri/Tenof Alafen38$156,276
DovatoDolutegravir Sodium/Lamivudine49$143,184
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$95,512
ValacyclovirValacyclovir Hcl26$774
CholestyramineCholestyramine (With Sugar)12$758
Atorvastatin Calcium56$394
Albuterol Sulfate HfaAlbuterol Sulfate18$356
Spironolactone12$348
Estradiol12$176
Gabapentin15$113
Bupropion XlBupropion Hcl12$106
Levocetirizine Dihydrochloride13$81
Pantoprazole Sodium33$81
Levothyroxine Sodium12$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$1,705$376,75791 claims
Viiv Healthcare CompanyDovato$2,831$143,18449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.

Other women's health in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →